Special Issue "Sea Anemone Toxins"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 May 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Hiroshi Nagai
Department of Ocean Science, Tokyo University of Marine Science and Technology, 4-5-7 Konan, Minato-ku, Tokyo 108-8477, Japan
E-Mail: nagai@kaiyodai.ac.jp

Special Issue Information

Dear Colleagues,

The sea anemones belong to the phylum Cnidaria. The distinguishing feature of cnidarians is nematocysts, specialized venomous organs that the animals use mainly for capturing prey and protecting themselves from predators. This means all the cnidarians have venom. So far, a number of polypeptide toxins have been isolated and characterized from the sea anemones. Among these studies, ion-channel toxins and pore forming toxins have been characterized. Some ion channel toxins are revealed to be useful tools for biomedical and physiological science. The recent reports showed that sea anemones, including their toxins, are still attractive sources for novel bioactive compounds. This special issue will focus on biological activity, mode of action, ecological significance, isolation and characterization of bioactive compounds including toxins from the sea anemones.

Prof. Dr. Hiroshi Nagai
Guest Editor

Keywords

  • Cnidaria
  • sea anemone
  • biological activity
  • venom
  • toxin
  • bioactive compounds
  • polypeptide

Published Papers (5 papers)

Mar. Drugs 2012, 10(8), 1812-1851; doi:10.3390/md10081812
Received: 31 May 2012; in revised form: 9 July 2012 / Accepted: 25 July 2012 / Published: 22 August 2012
Show/Hide Abstract | Download PDF Full-text (16456 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2012, 10(7), 1605-1618; doi:10.3390/md10071605
Received: 4 June 2012; in revised form: 18 July 2012 / Accepted: 19 July 2012 / Published: 23 July 2012
Show/Hide Abstract | Download PDF Full-text (858 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2012, 10(7), 1582-1604; doi:10.3390/md10071582
Received: 31 May 2012; in revised form: 29 June 2012 / Accepted: 12 July 2012 / Published: 23 July 2012
Show/Hide Abstract | Download PDF Full-text (5387 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2012, 10(7), 1545-1565; doi:10.3390/md10071545
Received: 18 April 2012; in revised form: 4 July 2012 / Accepted: 11 July 2012 / Published: 19 July 2012
Show/Hide Abstract | Download PDF Full-text (4790 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2012, 10(7), 1511-1527; doi:10.3390/md10071511
Received: 30 May 2012; in revised form: 14 June 2012 / Accepted: 6 July 2012 / Published: 16 July 2012
Show/Hide Abstract | Download PDF Full-text (613 KB) | View HTML Full-text | Download XML Full-text

Last update: 27 February 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert